News - GlaxoSmithKline, Licensing

Filter

Current filters:

GlaxoSmithKlineLicensing

Popular Filters

1 to 25 of 45 results

GlaxoSmithKline surprises with mega-dollar deal for cancer program

GlaxoSmithKline surprises with mega-dollar deal for cancer program

02-06-2014

UK biotech firm Adaptimmune revealed this morning that it has entered into a collaboration and licensing…

AdaptimmuneBiotechnologyGlaxoSmithKlineLicensingOncologyResearch

GlaxoSmithKline divests rights to Treximet to Pernix for $250 million

15-05-2014

UK pharma giant GlaxoSmithKline will divest all of its rights to migraine drug Treximet (sumatriptan/naproxen…

GlaxoSmithKlineLicensingNeurologicalPernix TherapeuticsPharmaceuticalPozenTreximetUSA

Epizyme earns $4 million milestone under GSK collaboration

22-04-2014

US clinical-stage biopharma firm Epizyme announced the achievement of the lead candidate milestone for…

BiotechnologyEpizymeFinancialGlaxoSmithKlineLicensingOncology

Prosonix and Mylan in deal for Flixotide and Flovent generics

15-04-2014

Prosonix, a UK-based company which is developing a portfolio of inhaled “Respiratory Medicines by Design,”…

FloventGenericsGlaxoSmithKlineGlobalLicensingMylan LaboratoriesProsonixRespiratory and Pulmonary

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

Amgen and GSK end marketing agreement for osteoporosis drug Prolia

04-04-2014

World leading independent biotech firm Amgen revealed in a Securities and Exchange Commission filing…

AmgenAnti-Arthritics/RheumaticsBiotechnologyGlaxoSmithKlineLicensingProliaXgeva

GlaxoSmithKline returns Duchenne drug rights to Prosensa

GlaxoSmithKline returns Duchenne drug rights to Prosensa

13-01-2014

UK pharma giant GlaxoSmithKline says that its partner, Dutch biotech firm Prosensa has regained all rights…

BiotechnologydrisapersenGlaxoSmithKlineLicensingProsensaRare diseases

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

Santaris Pharma in deal with GlaxoSmithKline to develop RNA-targeted medicines

13-01-2014

Santaris Pharma, a Denmark-based clinical-stage biopharma company, has signed an agreement with UK drug…

GlaxoSmithKlineLicensingPharmaceuticalSantaris Pharma

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

Big news day for Amicus, with change in GSK deal, an acquisition and restructuring

22-11-2013

US biotech firm Amicus Therapeutics saw its shares fall 4.2% to $2.03 by mid-morning trading on Thursday,…

Amicus TherapeuticsBiotechnologyCallidus BiopharmaFinancialGlaxoSmithKlineLicensingManagementMergers & AcquisitionsmigalastatRare diseases

Immunocore makes progress in deal with GSK

Immunocore makes progress in deal with GSK

07-11-2013

UK-based biotech firm Immunocore has achieved its first milestone in its major research and licensing…

EuropeFinancialGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearchUK

Janssen gains rights to Ph II hepatitis C candidate from GSK

08-10-2013

Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

Isis earns milestone payments from GlaxoSmithKline

Isis earns milestone payments from GlaxoSmithKline

07-10-2013

US biotech firm Isis Pharmaceuticals says that UK pharma giant GlaxoSmithKline has added a development…

BiotechnologyFinancialGlaxoSmithKlineIsis PharmaceuticalsLicensingPharmaceuticalRare diseases

GlaxoSmithKline returns rights to vercirnon

19-09-2013

US drug developer ChemoCentryx (Nasdaq: CCXI) says that partner GlaxoSmithKline (LSE: GSK), the UK’s…

ChemoCentryxGastro-intestinalsGlaxoSmithKlineLicensingNorth AmericaPharmaceuticalvercirnon

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

Elan pays $1 billion for a 21% share of Theravance royalties on four respiratory programs

13-05-2013

US biotech firm Theravance (Nasdaq: THRX) has entered into a royalty participation agreement wherein…

Anoro ElliptaBiotechnologyBreo ElliptaElanFinancialGlaxoSmithKlineLicensingPharmaceuticalRespiratory and PulmonaryTheravance

GSK returns IPX066 rights to Impax; Merck & Co and Pfizer link up on diabetes drug

30-04-2013

US biotech firm Impax Laboratories (Nasdaq: IPXL) saw its shares fall 2% to $17.32 in premarket trading,…

BiotechnologyDiabetesertugliflozinGlaxoSmithKlineImpax LaboratoriesIPX066LicensingMerck & CoNeurologicalPfizerPharmaceuticalResearch

Briefs: Eddingpharm deal with GSK China for Tykerb; AEterna Zentaris and Ergomed link on AEZS-108

10-04-2013

Chinese drugmaker Eddingpharm has entered into a collaboration agreement with UK pharma giant GlaxoSmithKline's…

AEterna ZentarisAEZS-108Asia-PacificErgomed Clinical ResarchGlaxoSmithKlineLicensingOncologyPharmaceuticalResearchTykerb

Briefs: Roche deal with Chiasma; Vasella payout; FDA priority review for dolutegravir

18-02-2013

Swiss drug major Roche (ROG: SIX) has entered into an agreement to develop and commercialize privately…

Anti-viralsdolutegravirGlaxoSmithKlineLicensingManagementNovartisOctreotide AcetatePharmaceuticalRare diseasesRegulationRocheViiV Healthcare

Amgen in $180 mill deal with BIND; Priaxon accord with GlaxoSmithKline

09-01-2013

BIND Biosciences, a US clinical stage investor backed company, and Amgen (Nasdaq: AMNG), the world's…

AmgenBIND BiosciencesBiotechnologyGlaxoSmithKlineLicensingOncologyPharmaceuticalPriaxon

Isis Pharma/GlaxoSmithKline's ISIS-TTR Rx gains US fast-track designation

14-12-2012

In what has been a busy newsflow few days for USA-based Isis Pharmaceutical (Nasdaq: ISIS), the company…

BiotechnologyGlaxoSmithKlineIsis PharmaceuticalsISIS-TTR.RXLicensingNorth AmericaPharmaceuticalRare diseasesRegulation

UT MD Anderson signs potentially lucrative deal with GlaxoSmithKline

10-12-2012

The University of Texas MD Anderson Cancer Center, one of the world's leading cancer research and treatment…

GlaxoSmithKlineLicensingOncologyPharmaceuticalResearch

GlaxoSmithKline gives up on XenoPort Horizant collaboration

09-11-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) says that it has reached an agreement with US partner XenoPort…

GlaxoSmithKlineHorizantLicensingNeurologicalPharmaceuticalXenoPort

1 to 25 of 45 results

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top